Could a common supplement tame multiple sclerosis?

NCT ID NCT07263607

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding taurine, a natural amino acid, to standard multiple sclerosis (MS) medications can improve outcomes. About 80 adults with relapsing-remitting MS will either continue their usual drugs or add daily taurine for 24 months. Researchers will track brain lesions, relapses, disability, and gut health to see if taurine offers extra protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
taurine
What this could lead to
If it works, adding taurine to standard MS therapy could help reduce brain damage, relapses, and slow disability progression.
What could go wrong
This is a small, early-phase trial with only 80 people. Taurine may show no added benefit over standard drugs, and results may not apply to all MS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.